Fulcrum Halts Lead Sickle Cell Drug Program, Initiates Strategic Review
FULC is trading near its 52-week low of $5.88 (30% below the low).
Summary
Fulcrum Therapeutics has discontinued its lead sickle cell disease program, pociredir, due to FDA concerns over malignancy risk associated with the PRC2 inhibitor class. This decision directly reverses the positive clinical data and extended cash runway announced for pociredir just over a month ago. The company is now initiating a comprehensive review of strategic alternatives, including a potential sale or merger, and is significantly reducing operating expenses. This is an existential event for the clinical-stage biotech, eliminating its primary value driver and forcing a complete re-evaluation of its future.
At the time of this announcement, FULC was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $427.8M. The 52-week trading range was $5.88 to $15.74. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.